3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
32
Myelodysplastic Syndromes
20
Leukemia, Myelomonocytic, Chronic
12
Myeloproliferative Disorders
2
Leukemia, Biphenotypic, Acute
2
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Patient Preference
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Multiple Myeloma
1
Leukemia, Myeloid, Chronic-Phase
1
GATA2 Deficiency
1
Colorectal Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
venetoclax
27
Cyclophosphamide
18
Azacitidine
13
fludarabine
12
ibrutinib
10
Busulfan
10
fludarabine phosphate
9
Rituximab
8
Mycophenolic Acid
8
Methotrexate
8
Cytarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Clofarabine
7
Therapeutics
6
Melphalan
6
Antilymphocyte Serum
6
obinutuzumab
5
Tacrolimus
5
Surveys and Questionnaires
5
Stem Cell Transplantation
5
Mesna
5
Exercise
5
Cyclosporine
5
vosaroxin
4
trametinib
4
thymoglobulin
4
ruxolitinib
4
ponatinib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
decitabine and cedazuridine drug combination
×
Other hematologic neoplasm
×
Clear all
NCT06351306
2025-03-24
DEC-C and Thioguanine for R/R AML
Columbia University
Phase 2
Withdrawn